Compare USBC & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | USBC | RCEL |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | 31 | 226 |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.0M | 132.0M |
| IPO Year | N/A | N/A |
| Metric | USBC | RCEL |
|---|---|---|
| Price | $0.34 | $5.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.88 |
| AVG Volume (30 Days) | ★ 421.3K | 204.2K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $17.17 |
| Revenue Next Year | N/A | $49.82 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $3.22 |
| 52 Week High | $1.97 | $10.28 |
| Indicator | USBC | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 46.22 | 72.28 |
| Support Level | N/A | $4.92 |
| Resistance Level | $0.42 | $5.89 |
| Average True Range (ATR) | 0.03 | 0.31 |
| MACD | 0.00 | 0.19 |
| Stochastic Oscillator | 23.62 | 87.07 |
USBC Inc is a multi-disciplinary technology company that is an innovator in digital financial technologies. The company develops financial services including digital assets and banking solutions, as well as non-invasive health monitoring research. USBC has implemented a Bitcoin treasury strategy to support development and research across its various divisions. A key focus is the further development of its tokenized deposit program, a tokenized representation of a U.S.-dollar-denominated bank deposit account that operates on blockchain technology and is embedded with digital identity, alongside its legacy non-invasive sensor technology business, with the objective of creating long-term shareholder value in an evolving financial landscape.
Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.